Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Relative Value
The Relative Value of one CNTA stock under the Base Case scenario is 3.58 USD. Compared to the current market price of 9.47 USD, Centessa Pharmaceuticals PLC is Overvalued by 62%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
CNTA Competitors Multiples
Centessa Pharmaceuticals PLC Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
UK |
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
1.1B USD | 153.6 | -7 | -5.1 | -5.1 | ||
US |
Abbvie Inc
NYSE:ABBV
|
289.2B USD | 5.3 | 60 | 13 | 19.9 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
166.7B USD | 5.9 | 24.8 | 17.9 | 26.8 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
104.7B USD | 8 | 26.5 | 17.8 | 19.6 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.4B USD | 10.5 | 28.6 | 22.8 | 23.9 | ||
AU |
CSL Ltd
ASX:CSL
|
133.2B AUD | 6.2 | 35.6 | 21.6 | 26.7 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
80.7B USD | 2.9 | 166.8 | 6.7 | 8.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
47.8B USD | 7 | -10.1 | -11 | -9.4 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.7B USD | 3.3 | 27.1 | 13.9 | 17.4 | ||
KR |
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |